Cancers, Vol. 12, Pages 2414: Front-Line Maintenance Therapy in Advanced Ovarian Cancer —Current Advances and Perspectives

Cancers, Vol. 12, Pages 2414: Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives Cancers doi: 10.3390/cancers12092414 Authors: Thibaut Reverdy Christophe Sajous Julien Péron Olivier Glehen Naoual Bakrin Witold Gertych Jonathan Lopez Benoit You Gilles Freyer Ovarian tumor is the gynecological cancer associated with the highest mortality. Most diseases are diagnosed at an advanced stage, which impairs the chances of prolonged complete remission. The standard front-line treatment of advanced stages combines surgery in an expert center with platinum-based chemotherapy. Most patients experience a relapse in the years following the initial treatment. During the last decade, anti-angiogenic agents used in the maintenance setting improved progression free survival (PFS) over chemotherapy alone. More recently, PARP inhibitors demonstrated substantial efficacy, mainly in patients with germinal or somatic BRCA mutations or other homologous recombination deficiencies (HRD), all involved in double strand DNA Damage Repair (DDR). Other therapeutic paradigms are currently being explored, including combinations of immune-checkpoints inhibitors, chemotherapy, bevacizumab and PARP inhibitors. In addition to these clinical advances, molecular characterization of the tumors and their correlations with drugs efficacy are needed to better understand which patient will benefit the most from the various treatments available to date.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research